Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
Jerome Fayette, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M Harari, Tibor Csoszi, Dana Cernea, Paul O'Brien, William D Hanley, Amy V Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan B Vermorken
Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2016
Awarded by Cancer Research UK
This work was supported by Genentech, Inc., South San Francisco, CA, USA. CN was supported by Cancer Research UK Programme Grant A13407 and the RM/ICR NIHR Biomedical Research Centre.